Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy
Year: 2017
Type: article
Abstract: Viral infections lead to alarmin release and elicit potent cytotoxic effector T lymphocyte (CTL eff ) responses. Conversely, the induction of protective tumour-specific CTL eff and their recruitment into the tumour remain challenging tasks. Here we show that lymphocytic choriomeningitis virus (LCMV) can be engineered to serve as a replication competent, stably-attenuated immunotherapy vector (artLCMV). artLCMV delivers tumour-associated antigens to dendritic cells for efficient CTL priming. Unlike replication-deficient vectors, artLCMV targets also lymphoid tissue stroma cells expressing the alarmin interleukin-33. By triggering interleukin-33 signals, artLCMV elicits CTL eff responses of higher magnitude and functionality than those induced by replication-deficient vectors. Superior anti-tumour efficacy of artLCMV immunotherapy depends on interleukin-33 signalling, and a massive CTL eff influx triggers an inflammatory conversion of the tumour microenvironment. Our observations suggest that replicating viral delivery systems can release alarmins for improved anti-tumour efficacy. These mechanistic insights may outweigh safety concerns around replicating viral vectors in cancer immunotherapy.
Source: Nature Communications
DOI: 10.1038/ncomms15327
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $6,990
Funders: National Science Foundation, Universität Basel, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Université de Genève, Klaus Tschira Stiftung, Universität Innsbruck, Institute of Genetics and Genomics of Geneva, National Institute of Allergy and Infectious Diseases
OpenAlex ID: W2617873219
